Blau Farmacêutica is a Brazilian maker of complex hospital medicines — the kind used in oncology, immunology, and intensive care — that quietly became one of Latin America's most relevant specialty drug producers. Full nameBlau Farmacêutica S.A. Tickers / exchangeBLAU3 — B3 (São Paulo) HeadquartersCotia, São Paulo, Brazil SectorHealthcare — specialty & generic drugs EmployeesNot disclosed in available sources Market valueR$ 2.37 billion (US$ 458 million) Yearly salesR$ 1.79 billion (US$ 346 million) Net profitR$ 295 million (US$ 57 million) Net margin13.1% Return on equity10.3% Price-to-earnings10.2 Dividend yield0.02% Websiteblau.com What …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
Brazil’s Blau Farmacêutica Profit Drops 34% on Tender Delay but Biotech Pipeline Accelerates
Blau Farmacêutica, GPA, and Fleury in Q3 2025: Growth, Challenges, and Strategic Moves
Financial Performance of Blau Farmacêutica, Estapar, and InterCement in Q4 2024
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →